Abbott, a global healthcare company, has introduced a new continuous glucose monitor (CGM) system designed not only for people with diabetes but also for those looking to enhance their overall health and wellness. Unlike traditional CGMs used primarily for real-time blood sugar level tracking, Abbott's Lingo system aims to bridge the gap between healthcare and preventative measures.

The Lingo system features a small biosensor that attaches to the back of the arm and can be worn for up to 14 days. This biosensor continuously monitors blood sugar levels 24/7, providing valuable data that is sent directly to the Lingo smartphone app. Through the app, users can gain insights and take control of their health by managing glucose spikes, weight, and sleep patterns.

According to Olivier Ropars, the vice president of Abbott's Lingo business, there is growing interest in tracking biomarkers that offer insights into one's health and wellness, particularly those previously undetectable by consumer-grade trackers. With Lingo, Abbott aims to meet this demand and provide users with valuable information translated from glucose data.

Fred St. Goar, a cardiologist and medical director of El Camino Health Heart and Vascular Institute, emphasized the importance of physical activity and nutrition in managing glucose variability. He stated that while glucose spikes are normal, minimizing them along with crashes can lead to various short-term and long-term health benefits.

Abbott's entry into the market comes as Dexcom, a rival company, recently introduced its own over-the-counter CGM at an affordable price of $89. Dexcom's monitor is suitable for both type 2 diabetes patients who do not take insulin and individuals aiming to monitor their glucose levels.

In June, Abbott received approval from the Food and Drug Administration (FDA) for a second over-the-counter CGM designed for type 2 diabetes patients. However, an official release date for this particular monitor has not yet been announced.

With the unveiling of the Lingo system, Abbott is positioning itself as a leader in the CGM market, catering not just to diabetes patients but also to health-conscious individuals seeking to improve their well-being. The ability to monitor important biomarkers such as glucose levels opens up a world of possibilities for better health management and prevention.

Abbott's commitment to innovation in the field of continuous glucose monitoring is likely to revolutionize how people approach their health and take proactive steps towards a healthier future.